{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T18:51:09Z","timestamp":1783536669347,"version":"3.55.0"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T00:00:00Z","timestamp":1589760000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["RESIST \\u2013 EXC 2155"],"award-info":[{"award-number":["RESIST \\u2013 EXC 2155"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["EXC-2189"],"award-info":[{"award-number":["EXC-2189"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["39087428"],"award-info":[{"award-number":["39087428"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["390939984"],"award-info":[{"award-number":["390939984"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["GR1617\/14\\u20131\/iPAD"],"award-info":[{"award-number":["GR1617\/14\\u20131\/iPAD"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["GAIN_01GM1910A"],"award-info":[{"award-number":["GAIN_01GM1910A"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005646","name":"Actelion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005646","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials Communications"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.conctc.2020.100575","type":"journal-article","created":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T02:38:56Z","timestamp":1590719936000},"page":"100575","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Safety and efficacy of abatacept in patients with treatment-resistant SARCoidosis (ABASARC) \u2013 protocol for a multi-center, single-arm phase IIa trial"],"prefix":"10.1016","volume":"19","author":[{"given":"Bj\u00f6rn C.","family":"Frye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina Caroline","family":"Rump","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6444-9208","authenticated-orcid":false,"given":"Annette","family":"Uhlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Schubach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8091-1589","authenticated-orcid":false,"given":"Gabriele","family":"Ihorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bodo","family":"Grimbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8021-9798","authenticated-orcid":false,"given":"Gernot","family":"Zissel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim M\u00fcller","family":"Quernheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9923","key":"10.1016\/j.conctc.2020.100575_bib1","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(13)60680-7","article-title":"Sarcoidosis","volume":"383","author":"Valeyre","year":"2014","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.conctc.2020.100575_bib2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-019-0096-x","article-title":"Sarcoidosis","volume":"5","author":"Grunewald","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"2","key":"10.1016\/j.conctc.2020.100575_bib3","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1164\/ajrccm.160.2.ats4-99","volume":"160","year":"1999","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.conctc.2020.100575_bib4","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1055\/s-0034-1376861","article-title":"Cellular activation in the immune response of sarcoidosis","volume":"35","author":"Zissel","year":"2014","journal-title":"Semin. Respir. Crit. Care Med."},{"issue":"4","key":"10.1016\/j.conctc.2020.100575_bib5","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1055\/s-0030-1262208","article-title":"Immunologic response of sarcoidosis","volume":"31","author":"Zissel","year":"2010","journal-title":"Semin. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.conctc.2020.100575_bib6","first-page":"CD001114","article-title":"Corticosteroids for pulmonary sarcoidosis","author":"Paramothayan","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"issue":"10","key":"10.1016\/j.conctc.2020.100575_bib7","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1001\/jama.287.10.1301","article-title":"Corticosteroid therapy in pulmonary sarcoidosis: a systematic review","volume":"287","author":"Paramothayan","year":"2002","journal-title":"J. Am. Med. Assoc."},{"issue":"1","key":"10.1016\/j.conctc.2020.100575_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rmed.2007.08.010","article-title":"Treatments for pulmonary sarcoidosis","volume":"102","author":"Paramothayan","year":"2008","journal-title":"Respir. Med."},{"issue":"3","key":"10.1016\/j.conctc.2020.100575_bib9","first-page":"CD003536","article-title":"Immunosuppressive and cytotoxic therapy for pulmonary sarcoidosis","author":"Paramothayan","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.conctc.2020.100575_bib10","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1517\/14728220903449244","article-title":"Targeting the TNF-alpha pathway in sarcoidosis","volume":"14","author":"Antoniu","year":"2010","journal-title":"Expert Opin. Ther. Targets"},{"issue":"2","key":"10.1016\/j.conctc.2020.100575_bib11","first-page":"76","article-title":"Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them","volume":"25","author":"Baughman","year":"2008","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"issue":"7","key":"10.1016\/j.conctc.2020.100575_bib12","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","article-title":"Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement","volume":"174","author":"Baughman","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"6","key":"10.1016\/j.conctc.2020.100575_bib13","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1128\/CVI.00337-10","article-title":"Inflammatory profile and response to anti-tumor necrosis factor therapy in patients with chronic pulmonary sarcoidosis","volume":"18","author":"Loza","year":"2011","journal-title":"Clin. Vaccine Immunol."},{"issue":"6","key":"10.1016\/j.conctc.2020.100575_bib14","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1183\/09031936.00169413","article-title":"Association of the TNF-alpha G-308A polymorphism with TNF-inhibitor response in sarcoidosis","volume":"43","author":"Wijnen","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.conctc.2020.100575_bib15","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12931-015-0265-8","article-title":"Impaired survival of regulatory T cells in pulmonary sarcoidosis","volume":"16","author":"Broos","year":"2015","journal-title":"Respir. Res."},{"issue":"2","key":"10.1016\/j.conctc.2020.100575_bib16","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1084\/jem.20050648","article-title":"The immune paradox of sarcoidosis and regulatory T cells","volume":"203","author":"Miyara","year":"2006","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.conctc.2020.100575_bib17","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1164\/rccm.200909-1451OC","article-title":"Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis","volume":"182","author":"Prasse","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"10.1016\/j.conctc.2020.100575_bib18","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ccm.2015.08.016","article-title":"Cellular players in the immunopathogenesis of sarcoidosis","volume":"36","author":"Zissel","year":"2015","journal-title":"Clin. Chest Med."},{"issue":"1","key":"10.1016\/j.conctc.2020.100575_bib19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-2007-970329","article-title":"Sarcoidosis--immunopathogenetic concepts","volume":"28","author":"Zissel","year":"2007","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"10.1016\/j.conctc.2020.100575_bib20","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1101\/sqb.1999.64.303","article-title":"CTLA-4--the costimulatory molecule that doesn't: regulation of T-cell responses by inhibition","volume":"64","author":"Chambers","year":"1999","journal-title":"Cold Spring Harbor Symp. Quant. Biol."},{"key":"10.1016\/j.conctc.2020.100575_bib21","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1146\/annurev.immunol.19.1.565","article-title":"CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy","volume":"19","author":"Chambers","year":"2001","journal-title":"Annu. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.conctc.2020.100575_bib22","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/85251","article-title":"The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function","volume":"2","author":"Coyle","year":"2001","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.conctc.2020.100575_bib23","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1046\/j.1365-2567.2000.00121.x","article-title":"CD28, CTLA-4 and their ligands: who does what and to whom?","volume":"101","author":"Sansom","year":"2000","journal-title":"Immunology"},{"issue":"6029","key":"10.1016\/j.conctc.2020.100575_bib24","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1126\/science.1202947","article-title":"Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4","volume":"332","author":"Qureshi","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.conctc.2020.100575_bib25","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/B978-0-12-800147-9.00004-2","article-title":"A transendocytosis perspective on the CD28\/CTLA-4 pathway","volume":"124","author":"Soskic","year":"2014","journal-title":"Adv. Immunol."},{"issue":"34","key":"10.1016\/j.conctc.2020.100575_bib26","doi-asserted-by":"crossref","first-page":"13756","DOI":"10.1073\/pnas.0706509104","article-title":"Induction of autoimmune disease in CTLA-4-\/- mice depends on a specific CD28 motif that is required for in vivo costimulation","volume":"104","author":"Tai","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5238","key":"10.1016\/j.conctc.2020.100575_bib27","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1126\/science.270.5238.985","article-title":"Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4","volume":"270","author":"Waterhouse","year":"1995","journal-title":"Science"},{"issue":"6939","key":"10.1016\/j.conctc.2020.100575_bib28","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature01621","article-title":"Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease","volume":"423","author":"Ueda","year":"2003","journal-title":"Nature"},{"issue":"6204","key":"10.1016\/j.conctc.2020.100575_bib29","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1126\/science.1255904","article-title":"Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4","volume":"345","author":"Kuehn","year":"2014","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.conctc.2020.100575_bib30","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/nm.3746","article-title":"Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations","volume":"20","author":"Schubert","year":"2014","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.conctc.2020.100575_bib31","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1136\/gutjnl-2014-308541","article-title":"Early-onset Crohn\u2019s disease and autoimmunity associated with a variant in CTLA-4","volume":"64","author":"Zeissig","year":"2014","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.conctc.2020.100575_bib32","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1164\/rccm.201503-0635LE","article-title":"Decreased cytotoxic T-lymphocyte antigen 4 expression on regulatory T cells and Th17 cells in sarcoidosis: double trouble?","volume":"192","author":"Broos","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.conctc.2020.100575_bib33","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med."},{"issue":"3","key":"10.1016\/j.conctc.2020.100575_bib34","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.chest.2018.03.056","article-title":"Drug-induced sarcoidosis-like reactions","volume":"154","author":"Chopra","year":"2018","journal-title":"Chest"},{"issue":"8","key":"10.1016\/j.conctc.2020.100575_bib35","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/CJI.0000000000000181","article-title":"Sarcoidosis following anti-PD-1 and anti-CTLA-4 therapy for metastatic melanoma","volume":"40","author":"Reddy","year":"2017","journal-title":"J. Immunother."},{"issue":"3","key":"10.1016\/j.conctc.2020.100575_bib36","first-page":"318","article-title":"Technology evaluation: abatacept, bristol-myers Squibb","volume":"6","author":"Dumont","year":"2004","journal-title":"Curr. Opin. Mol. Therapeut."},{"issue":"12","key":"10.1016\/j.conctc.2020.100575_bib37","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/ncprheum0345","article-title":"Drug Insight: abatacept for the treatment of rheumatoid arthritis","volume":"2","author":"Ruderman","year":"2006","journal-title":"Nat. Clin. Pract. Rheumatol."},{"issue":"11","key":"10.1016\/j.conctc.2020.100575_bib38","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","article-title":"Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition","volume":"353","author":"Genovese","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.conctc.2020.100575_bib39","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1136\/ard.2007.074773","article-title":"Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy","volume":"67","author":"Genovese","year":"2008","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.conctc.2020.100575_bib40","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/art.30176","article-title":"Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial","volume":"63","author":"Mease","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.conctc.2020.100575_bib41","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12955-019-1131-z","article-title":"Translation and psychometric properties of the King's Sarcoidosis Questionnaire (KSQ) in German language","volume":"17","author":"Farin","year":"2019","journal-title":"Health Qual. Life Outcome"},{"issue":"1","key":"10.1016\/j.conctc.2020.100575_bib42","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1136\/thoraxjnl-2012-201962","article-title":"The development and validation of the King's Sarcoidosis Questionnaire for the assessment of health status","volume":"68","author":"Patel","year":"2013","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.conctc.2020.100575_bib43","first-page":"47","article-title":"[Monitoring sarcoidosis therapy with immunopathologic parameters]","volume":"48","author":"Muller-Quernheim","year":"1994","journal-title":"Pneumologie"},{"issue":"1","key":"10.1016\/j.conctc.2020.100575_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-017-1488-5","article-title":"Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting","volume":"20","author":"Alten","year":"2018","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.conctc.2020.100575_bib45","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1007\/s00296-018-4173-3","article-title":"On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis","volume":"38","author":"Bykerk","year":"2018","journal-title":"Rheumatol. Int."},{"issue":"155","key":"10.1016\/j.conctc.2020.100575_bib46","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0146-2019","article-title":"Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis","volume":"29","author":"Rahaghi","year":"2020","journal-title":"Eur. Respir. Rev."},{"issue":"4","key":"10.1016\/j.conctc.2020.100575_bib47","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1055\/s-0037-1603768","article-title":"Sarcoidosis: drugs under investigation","volume":"38","author":"Schupp","year":"2017","journal-title":"Semin. Respir. Crit. Care Med."},{"issue":"5","key":"10.1016\/j.conctc.2020.100575_bib48","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/MCP.0000000000000303","article-title":"T-cell immunology in sarcoidosis: disruption of a delicate balance between helper and regulatory T-cells","volume":"22","author":"Broos","year":"2016","journal-title":"Curr. Opin. Pulm. Med."},{"issue":"6","key":"10.1016\/j.conctc.2020.100575_bib49","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1440-1843.2009.01600.x","article-title":"Non-invasive biomarkers in pulmonary fibrosis","volume":"14","author":"Prasse","year":"2009","journal-title":"Respirology"},{"issue":"11","key":"10.1016\/j.conctc.2020.100575_bib50","doi-asserted-by":"crossref","first-page":"6265","DOI":"10.21873\/anticanres.13836","article-title":"The impact of antibiotics on prognosis of metastatic renal cell carcinoma in Japanese patients treated with immune checkpoint inhibitors","volume":"39","author":"Ueda","year":"2019","journal-title":"Anticancer Res."},{"issue":"5","key":"10.1016\/j.conctc.2020.100575_bib51","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/MCP.0000000000000078","article-title":"Cytotoxic agents in sarcoidosis: which one should we choose?","volume":"20","author":"Vorselaars","year":"2014","journal-title":"Curr. Opin. Pulm. Med."},{"issue":"3","key":"10.1016\/j.conctc.2020.100575_bib52","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1378\/chest.12-1728","article-title":"Methotrexate vs azathioprine in second-line therapy of sarcoidosis","volume":"144","author":"Vorselaars","year":"2013","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.conctc.2020.100575_bib53","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/acr.23824","article-title":"Risk of hospitalized infection and initiation of abatacept versus TNF inhibitors among patients with rheumatoid arthritis: a propensity score-matched cohort study","volume":"72","author":"Chen","year":"2018","journal-title":"Arthritis Care Res. (Hoboken)"},{"issue":"2","key":"10.1016\/j.conctc.2020.100575_bib54","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00296-018-4196-9","article-title":"Risk of hospitalization for heart failure in rheumatoid arthritis patients treated with etanercept and abatacept","volume":"39","author":"Generali","year":"2019","journal-title":"Rheumatol. Int."},{"issue":"16","key":"10.1016\/j.conctc.2020.100575_bib55","first-page":"1596","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"381","author":"Distler","year":"2019","journal-title":"Reply. N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.conctc.2020.100575_bib56","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.conctc.2020.100575_bib57","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.conctc.2020.100575_bib58","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1183\/09031936.00051907","article-title":"Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial","volume":"31","author":"Judson","year":"2008","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.conctc.2020.100575_bib59","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/joim.12973","article-title":"The value of bronchoalveolar lavage for discrimination between healthy and diseased individuals","volume":"287","author":"Frye","year":"2019","journal-title":"J. Intern. Med."},{"issue":"1","key":"10.1016\/j.conctc.2020.100575_bib60","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1183\/09031936.00227014","article-title":"Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis","volume":"46","author":"Vorselaars","year":"2015","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.conctc.2020.100575_bib61","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/thorax.58.4.339","article-title":"Development of a symptom specific health status measure for patients with chronic cough: leicester Cough Questionnaire (LCQ)","volume":"58","author":"Birring","year":"2003","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.conctc.2020.100575_bib62","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.rmed.2009.09.006","article-title":"The SF-36 and SGRQ: validity and first look at minimum important differences in IPF","volume":"104","author":"Swigris","year":"2010","journal-title":"Respir. Med."},{"issue":"187","key":"10.1016\/j.conctc.2020.100575_bib63","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/978-3-540-79842-2_16","article-title":"Clinical cough IV:what is the minimal important difference for the Leicester Cough Questionnaire?","author":"Raj","year":"2009","journal-title":"Handb. Exp. Pharmacol."},{"issue":"3","key":"10.1016\/j.conctc.2020.100575_bib64","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1055\/s-0034-1376863","article-title":"Sarcoidosis-associated pulmonary hypertension and lung transplantation for sarcoidosis","volume":"35","author":"Shino","year":"2014","journal-title":"Semin. Respir. Crit. Care Med."}],"container-title":["Contemporary Clinical Trials Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865420300594?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865420300594?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T23:30:59Z","timestamp":1778887859000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451865420300594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":64,"alternative-id":["S2451865420300594"],"URL":"https:\/\/doi.org\/10.1016\/j.conctc.2020.100575","relation":{},"ISSN":["2451-8654"],"issn-type":[{"value":"2451-8654","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of abatacept in patients with treatment-resistant SARCoidosis (ABASARC) \u2013 protocol for a multi-center, single-arm phase IIa trial","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.conctc.2020.100575","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100575"}}